Efficacy of second-line treatment for gemcitabine-refractory unresectable pancreatic cancer in a real-world setting
In the second-line treatment of pancreatic cancer, the efficacy of common treatment regimens is not significantly different, while a good performance status is the key factor influencing survival. Thus, it is recommended that supportive care be enhanced concurrently with systemic therapy in patients with pancreatic cancer.
Authors
- Jishu Wei (ORCID: https://orcid.org/0000-0003-0529-272X)
- Yang Wu (ORCID: https://orcid.org/0000-0002-0906-9667)
- Wentao Gao (ORCID: https://orcid.org/0000-0002-3332-8112)
- Bin Xiao (ORCID: https://orcid.org/0000-0001-7159-4406)
- Dong Xu (ORCID: https://orcid.org/0009-0007-6202-3864)
- Min Tu (ORCID: https://orcid.org/0000-0003-1017-8825)
- Kuirong Jiang (ORCID: https://orcid.org/0000-0001-9512-6463)
- Nan Lv
- Junli Wu (ORCID: https://orcid.org/0000-0002-4407-0516)
- Qianqian Wang (ORCID: https://orcid.org/0009-0005-9308-0584)
Institutions
- Nanjing Medical University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1186/s12885-025-14601-2
- Citations
- 1
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05